CN105106355A - Chewable tablets for improving eyesight - Google Patents
Chewable tablets for improving eyesight Download PDFInfo
- Publication number
- CN105106355A CN105106355A CN201510577765.6A CN201510577765A CN105106355A CN 105106355 A CN105106355 A CN 105106355A CN 201510577765 A CN201510577765 A CN 201510577765A CN 105106355 A CN105106355 A CN 105106355A
- Authority
- CN
- China
- Prior art keywords
- parts
- improving eyesight
- eyesight
- improving
- extract
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention discloses chewable tablets for improving eyesight. The chewable tablets for improving the eyesight is produced, by weight, 1-3 parts of wild chrysanthemum extract, 1-3 parts of hawthorn extract, 70-90 parts of maltitol, 2-4 parts of vitamin C, 5-10 parts of maltodextrin, 3-7 parts of soluble dietary fiber and 0.5-1.5 parts of magnesium stearate. The chewable tablets for improving the eyesight are purely natural, nutritional, health-care and capable of obviously improving the eyesight and eliminating eye fatigue.
Description
Technical field
The present invention relates to a kind of chewable tablet, particularly relate to a kind of improving eyesight chewable tablet.
Background technology
Myopia, names of disease of tcm.Be that eye is regulating under relaxed state, parallel rays is before the refraction back focus of the dioptric system of eye drops on retina.Ancient medical book is early recognized primary disease, is called that order can not hypermetropia, and having another name called can nearly timid disease far away, begins to claim myopia to " order is through great achievement ".By congenital generation, myopic degree the higher person is also known as myopia.The generation of myopia with hereditary, grow, the factors such as environment is relevant, but definite pathogeny is still under study for action.
Dialectical main points: insufficiency of vital energy and blood is demonstrate,proved, watching for a long time hematozemia, blood being the material foundation of QI, and blood deficiency gas is also empty, God Light can not be sent out more at a distance, dialectical with mistake eyesight, distant vision being blurred for main points.Liver and kidney two deficiency syndrome, innate deficiency, sun declined cloudy so that brilliance can not far and, therefore depending near and can not look far.Dialectical with distant vision being blurred since the childhood for main points.
The existing product for myopia mainly concentrates on medicine, does not have applicable health product.
Summary of the invention
For the deficiencies in the prior art, technical problem to be solved by this invention is to provide a kind of improving eyesight chewable tablet.
Technical problem of the present invention is implemented by following technical proposals:
A kind of improving eyesight chewable tablet, comprises following weight parts raw material: Flos Chrysanthemi Indici extract 1-3 part, Fructus Crataegi extract 1-3 part, maltose alcohol 70-90 part, Catergen-4 parts, maltodextrin 5-10 part, water soluble dietary fiber 3-7 part, magnesium stearate 0.5-1.5 part.
Preferably,
A kind of improving eyesight chewable tablet, comprises following weight parts raw material: Flos Chrysanthemi Indici extract 1-3 part, Fructus Crataegi extract 1-3 part, maltose alcohol 70-90 part, Catergen-4 parts, maltodextrin 5-10 part, water soluble dietary fiber 3-7 part, magnesium stearate 0.5-1.5 part, plant antistaling agent 0.2-0.6 part.
Described plant antistaling agent is deoxyschizandrin and/or schisandrin C.
Described plant antistaling agent is made up of 30-70wt% deoxyschizandrin and 30-70wt% schisandrin C.
Flos Chrysanthemi Indici extract, English name ChrysanthemumindicumL.P.E, latin name FlosChrysanthemiIndici, originate as the dry capitulum of feverfew Herba Dendranthematis indici.
Fructus Crataegi extract, English name HawthornP.E., latin name Fructuscrataegi, the mature fruit of originating as rosaceous plant Fructus Pyri Pashiae or Fructus Crataegi.
Get raw material after crushed, accurately take by formula proportion, mixing of materials is even; Add water-wet; Granulate; Drying, granulate, tabletting, can obtain improving eyesight chewable tablet of the present invention.
The present invention can make excess eye-using, visual function decline long period of operation computer, the personage of contact electromagnetic radiation person can life-time service; can vision protection, alleviate eyestrain, visual function descender, myope are taken; symptom can be made to alleviate, Be very effective.
Improving eyesight chewable tablet of the present invention, pure natural, nourishing healthy, can vision enhancing significantly, anti-eye strain.After interpolation plant antistaling agent, more easily preserve.
Detailed description of the invention
In embodiment: Flos Chrysanthemi Indici extract, the Flos Chrysanthemi Indici extract that Shaanxi Rui Kang biological engineering company limited produces.Fructus Crataegi extract, the Fructus Crataegi extract that Shaanxi Rui Kang biological engineering company limited produces.Maltose alcohol, the maltose alcohol that Shanghai Gan Yuan Industrial Co., Ltd. produces.Maltodextrin, the maltodextrin that Zhucheng Dongxiao Biotechnology Co., Ltd. produces.Water soluble dietary fiber, the water soluble dietary fiber that Shaanxi Sen Fu high-tech Industrial Co., Ltd. produces.
Embodiment 1-6
Get raw material after crushed, accurately take by formula proportion, mixing of materials is even; Add water-wet; Granulate; Drying, granulate, tabletting, can obtain improving eyesight chewable tablet of the present invention.
Table 1: improving eyesight formula of chewable tablets list position: gram
| Raw material | Embodiment 1 | Embodiment 2 | Embodiment 3 | Embodiment 4 | Embodiment 5 | Embodiment 6 |
| Flos Chrysanthemi Indici extract | 2 | 2 | 2 | 2 | 2 | 2 |
| Fructus Crataegi extract | 2 | 2 | 2 | 2 | 2 | 2 |
| Maltose alcohol | 80 | 80 | 80 | 80 | 80 | 80 |
| Vitamin C | 3 | 3 | 3 | 3 | 3 | 3 |
| Maltodextrin | 7 | 7 | 7 | 7 | 7 | 7 |
| Water soluble dietary fiber | 5 | 5 | 5 | 5 | 5 | 5 |
| Magnesium stearate | 1 | 1 | 1 | 1 | 1 | 1 |
| Deoxyschizandrin | 0.2 | 0.4 | - | - | 0.2 | - |
| Schisandrin C | 0.2 | - | 0.4 | - | - | 0.2 |
| Schisandrin B | - | - | - | 0.4 | 0.2 | 0.2 |
Deoxyschizandrin, No. CAS: 61281-38-7.Schisandrin B, No. CAS: 61281-37-6.Schisandrin C, No. CAS: 61301-33-5.
Deoxyschizandrin, schisandrin C not only have preservation and antisepsis effect, effectively can also improve asthenopia, and its successful is better than schisandrin B.
Improving eyesight chewable tablet of the present invention, pure natural, nourishing healthy, can vision enhancing significantly, anti-eye strain.
Test case 1
Test improving eyesight chewable tablet prepared by embodiment 1-6, be stored open under 40 DEG C and gravity-flow ventilation condition, sampling and testing after 10 days, measures total plate count under the microscope.Result is as shown in table 2.
Table 2: total plate count test chart
| Total plate count, cfu/g | |
| Embodiment 1 | 2.1×10 4 |
| Embodiment 2 | 4.2×10 4 |
| Embodiment 3 | 4.0×10 4 |
| Embodiment 4 | 6.3×10 4 |
| Embodiment 5 | 5.1×10 4 |
| Embodiment 6 | 5.0×10 4 |
After interpolation plant antistaling agent, total plate count obviously declines, and shelf life of products is significantly extended.
Test case 2
The present invention is according to Ministry of Public Health " health food inspection and assessment technical specification " (version in 2003), improving eyesight chewable tablet of the present invention is carried out to the effect assessment of the human feeding trial of 90 days by a definite date, chewed the improving eyesight chewable tablet 6 (every sheet 1 gram) of the embodiment of the present invention 1 every day.Result shows:
Test group right and left eyes distant vision all makes moderate progress than before test-meal, and difference has statistical significance (P<0.05); Comparing difference not statistically significant (P>0.05) before right and left eyes distant vision and test-meal after matched group test-meal.The eye symptom integration of test group is reduced to after taking 2.60 by taking 4.70 before tested material.
8-20 year, more than eyesight improving 2 row (standard logarithmic visual acuity chart sighting target), vision endurance improve 30%.
Conclusion: test proved invention improving eyesight chewable tablet has asthenopia releasing function effect to human body.
Claims (2)
1. an improving eyesight chewable tablet, comprises following weight parts raw material: Flos Chrysanthemi Indici extract 1-3 part, Fructus Crataegi extract 1-3 part, maltose alcohol 70-90 part, Catergen-4 parts, maltodextrin 5-10 part, water soluble dietary fiber 3-7 part, magnesium stearate 0.5-1.5 part.
2. an improving eyesight chewable tablet, comprises following weight parts raw material: Flos Chrysanthemi Indici extract 1-3 part, Fructus Crataegi extract 1-3 part, maltose alcohol 70-90 part, Catergen-4 parts, maltodextrin 5-10 part, water soluble dietary fiber 3-7 part, magnesium stearate 0.5-1.5 part, plant antistaling agent 0.2-0.6 part;
Described plant antistaling agent is made up of 30-70wt% deoxyschizandrin and 30-70wt% schisandrin C.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510577765.6A CN105106355A (en) | 2015-09-11 | 2015-09-11 | Chewable tablets for improving eyesight |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510577765.6A CN105106355A (en) | 2015-09-11 | 2015-09-11 | Chewable tablets for improving eyesight |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105106355A true CN105106355A (en) | 2015-12-02 |
Family
ID=54654633
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510577765.6A Pending CN105106355A (en) | 2015-09-11 | 2015-09-11 | Chewable tablets for improving eyesight |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105106355A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105558924A (en) * | 2015-12-29 | 2016-05-11 | 天津天狮生物发展有限公司 | Dietary fiber chewable tablet and preparation method thereof |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101810285A (en) * | 2009-12-28 | 2010-08-25 | 王福起 | Hawthorn food with function of improving eyesight and preparation method thereof |
| CN103083270A (en) * | 2013-02-25 | 2013-05-08 | 林继华 | Xanthophyll chewable tablet |
-
2015
- 2015-09-11 CN CN201510577765.6A patent/CN105106355A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101810285A (en) * | 2009-12-28 | 2010-08-25 | 王福起 | Hawthorn food with function of improving eyesight and preparation method thereof |
| CN103083270A (en) * | 2013-02-25 | 2013-05-08 | 林继华 | Xanthophyll chewable tablet |
Non-Patent Citations (3)
| Title |
|---|
| 叶兆伟: "《中药药理学》", 31 August 2015, 重庆大学出版社 * |
| 张媛媛等: "五味子抑菌成分的提取及在面制食品保鲜中的应用", 《粮油深加工及食品》 * |
| 柴瑞霞: "《最有效的糖尿病食疗》", 30 September 2014, 黑龙江科学技术出版社 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105558924A (en) * | 2015-12-29 | 2016-05-11 | 天津天狮生物发展有限公司 | Dietary fiber chewable tablet and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Jaffé | Health effects of non-centrifugal sugar (NCS): a review | |
| Mandalari et al. | Pistachio nuts (Pistacia vera L.): Production, nutrients, bioactives and novel health effects | |
| Seyidoglu et al. | A prominent superfood: Spirulina platensis | |
| Cai et al. | Practical application of antidiabetic efficacy of Lycium barbarum polysaccharide in patients with type 2 diabetes | |
| Wang et al. | Structure and inducing tumor cell apoptosis activity of polysaccharides isolated from Lentinus edodes | |
| Wang et al. | The effective mechanism of the polysaccharides from Panax ginseng on chronic fatigue syndrome | |
| Liao et al. | Characterisation of the chemical composition and in vitro anti-inflammation assessment of a novel lotus (Nelumbo nucifera Gaertn) plumule polysaccharide | |
| You et al. | A comparison study between different molecular weight polysaccharides derived from Lentinus edodes and their antioxidant activities in vivo | |
| Kilari et al. | Delayed progression of diabetic cataractogenesis and retinopathy by Litchi chinensis in STZ-induced diabetic rats | |
| Yang et al. | Antidiabetic effects of rice hull smoke extract in alloxan-induced diabetic mice | |
| Moradi et al. | The effect of okra (Abelmoschus esculentus) on lipid profiles and glycemic indices in Type 2 diabetic adults: Randomized double blinded trials | |
| Cheng | The growth performance and nonspecific immunity of red swamp crayfish Procambarus clarkia affected by dietary Rhodiola rosea polysaccharide | |
| Olvera-Sandoval et al. | Potential mechanisms of the improvement of glucose homeostasis in type 2 diabetes by pomegranate juice | |
| CN105168576A (en) | Blueberry chewable tablet | |
| Calabriso et al. | Non-celiac gluten sensitivity and protective role of dietary polyphenols | |
| Madrigal-Santillán et al. | Opuntia genus in human health: A comprehensive summary on its pharmacological, therapeutic and preventive properties. part 1 | |
| Tavakoli et al. | The case for a more holistic approach to dry eye disease: is it time to move beyond antibiotics? | |
| Xue et al. | Preventive and synbiotic effects of the soluble dietary fiber obtained from Lentinula edodes byproducts and Lactobacillus plantarum LP90 against dextran sulfate sodium‐induced colitis in mice | |
| Badjona et al. | Faba bean processing: Thermal and non-thermal processing on chemical, antinutritional factors, and pharmacological properties | |
| Wang et al. | Lycium genus polysaccharide: an overview of its extraction, structures, pharmacological activities and biological applications | |
| Yu et al. | Immunomodulatory effects of cinobufagin on murine lymphocytes and macrophages | |
| CN105168320A (en) | Lutein chewable tablet | |
| CN105106355A (en) | Chewable tablets for improving eyesight | |
| Niu et al. | Distinct role of Lycium barbarum L. polysaccharides in oxidative stress-related ocular diseases | |
| Liang et al. | Effect of high‐pressure processing on the polysaccharides content and antioxidant activity of fresh Dendrobium officinale juice |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20151202 |